Brought to you by 
Retinal implant start-up Pixium completes €34.5mm IPO in France
18 Jun 2014
Executive Summary
Pixium Vision (sensory neuromodulation to restore vision) raised €34.5mm ($47mm) in its IPO on Euronext Paris. The company sold 4.2mm shares (including full exercise of the extension clause; more than the 3.6mm planned) for €8.28, the bottom end of its €8.28-10.12 price range. Bpifrance Participations bought €8.5mm IPO shares (and adds a board member to Pixium), and existing investors Sofinnova, Abingworth, Omnes Capital, Innobio, and Seventure purchased €8.5mm.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Retinal implant start-up Pixium completes €34.5mm IPO in France
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice